Completed PHASE2 INTERVENTIONAL 3-arm NCT01740063

Phase 2B Study on Safety and Therapeutic Efficacy of DAS181 in Adult Subjects With Naturally Acquired Influenza

Randomized, Double-blind, Placebo-controlled Phase 2B Study on Safety and Therapeutic Efficacy of DAS181 in Adult Subjects With Naturally Acquired Influenza.

Sponsor: Ansun Biopharma, Inc.

Conditions Influenza

Interventions DAS181-F02 formulation DAS181-F04 formulation Placebo

Updated 7 times since 2017 Last updated: Jul 3, 2019 Started: Nov 30, 2012 Primary completion: Jan 31, 2014 Completion: Jan 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Influenza and is currently completed. Ansun Biopharma, Inc. leads this study, which shows 7 recorded versions since 2012 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Aug 2019 — Jan 2021 [monthly]

Completed PHASE2

Status: Unknown Status → Completed
Jun 2018 — Aug 2019 [monthly]

Unknown Status PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Unknown Status PHASE2
Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE2

First recorded

Nov 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ansun Biopharma, Inc.

Data source: Ansun Biopharma, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• San Diego, United States